Denmark: Novo Nordisk expands presence in sickle cell disease with Forma acquisition

Global healthcare company Novo Nordisk is to acquire Forma Therapeutics, a Nasdaq listed clinical-stage biopharmaceutical company focused on sickle cell disease (SCD) and rare blood disorders for US$20 per share in cash, representing a total equity value of US$1.1bn. The acquisition of Forma Therapeutics, including its lead development candidate, etavopivat, is aligned with Novo Nordisk’s…

You must be a HMI Subscriber to view this content.

Subscribe Now »